Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific
peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA
1/2 mutant or HRD+ solid tumors.
The main question[s] it aims to answer are:
- to evaluate the safety and tolerability of single agent and combination therapy
- to determine the recommended dose for Phase 2 of single agent and combination therapy
- to determine the pharmacokinetics of TNG348 as a single agent and in combination therapy
- to evaluate the initial antineoplastic activity as a single agent and in combination
therapy
Participants will receive study treatment until they experience an undesirable side effect,
their disease progresses or until they withdraw consent.